肝素诱导的血小板减少症患者队列的临床结局
该研究分析了442例近期暴露肝素且肝素-血小板因子4抗体检测阳性的患者,其中71例(16%)为肝素诱导的血小板减少症伴血栓形成(HIT-T),284例(64%)为孤立性HIT,87例(20%)无HIT。主要复合终点(死亡、截肢/坏疽或新发血栓)在三组的发生率分别为48%、36%和17%(P=0.01)。非肝素抗凝治疗与两个HIT组的复合终点事件减少均无关。
要点
- 输血后风险增加(HR 1.77,P=0.02),三组大出血发生率分别为48%、36%和16%(P=0.005)。
核心结论
- HIT患者死亡、截肢/坏疽、血栓形成和出血风险均较高。
- 非肝素抗凝治疗可能并非对所有患者均有益,应在仔细评估个体患者血栓和出血的相对风险后才考虑使用。
研究设计与样本
- 研究分析了442例近期暴露肝素且肝素-血小板因子4抗体检测阳性的患者数据。
主要发现
- 71例(16%)为HIT-T,284例(64%)为孤立性HIT,87例(20%)无HIT。
- 三组中分别有85%、58%和8%的患者4T评分处于中或高危。
- 三组分别有80%、56%和45%的患者起始非肝素抗凝治疗。
- 复合终点在三组的发生率分别为48%、36%和17%(P=0.01),其中分别有61%、38%和40%的患者正在接受非肝素抗凝治疗。
临床怎么用
- 原文结论指出非肝素抗凝治疗可能并非对所有患者均有益,应在仔细评估个体患者血栓和出血的相对风险后才考虑使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heparin-induced thrombocytopenia (HIT) is a thrombotic disorder usually prompting treatment with non-heparin anticoagulants. The benefits and risks of such treatments have not been fully assessed. METHODS: We analyzed data for 442 patients having a positive heparin-platelet factor 4 antibody test and recent heparin exposure. The primary outcome was a composite endpoint (death, limb amputation/gangrene, or new thrombosis). Secondary outcomes included bleeding and the effect of anticoagulation. FINDINGS: Seventy-one patients (16%) had HIT with thrombosis (HIT-T); 284 (64%) had HIT without thrombosis (isolated HIT); 87 (20%) did not have HIT. An intermediate or high "4T" score was found in 85%, 58%, and 8% of the three respective groups. Non-heparin anticoagulation was begun in 80%, 56%, and 45%. The composite endpoint occurred in 48%, 36%, and 17% (P = .01) of which 61%, 38%, and 40% were receiving non-heparin anticoagulation. Compared with the no HIT group, the composite endpoint was significantly more likely in HIT-T [HR 2.48 (1.35-4.55), P = .003)] and marginally more likely in isolated HIT [HR 1.66 (0.96-2.85), P = .071]. Importantly, risk increased (HR 1.77, P = .02) after platelet transfusion. Major bleeding occurred in 48%, 36%, and 16% of the three groups (P = .005). Non-heparin anticoagulation was not associated with a reduction in composite endpoint events in either HIT group. INTERPRETATION: HIT patients have high risks of death, limb amputation/gangrene, thrombosis, and bleeding. Non-heparin anticoagulant treatment may not benefit all patients and should be considered only after careful assessment of the relative risks of thrombosis and bleeding in individual patients.
引用
- Kuter DJ, Konkle BA, Hamza TH, et al. Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia. Am J Hematol. 2017. PMID: 28388835. doi:10.1002/ajh.24759
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。